Skip to main content
. 2017 Jan 19;8:14234. doi: 10.1038/ncomms14234

Figure 4. In vivo efficacy of 46B8 in influenza B mouse infection models.

Figure 4

(a) DBA/2 J mice were infected intranasally with a minimum lethal dose of B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966. At 24, 48 or 72 h post infection, mice received a single treatment of 46B8 or a control IgG intravenously at 15 mg kg−1. Survival curves are shown. Each group contains eight mice. Log-rank tests of all 46B8-treated groups versus the control in all infection models give P<0.05. (b) DBA/2 J mice were infected intranasally with a minimum lethal dose of B/Wisconsin/1/2010, B/Victoria/504/2000 or B/Massachusetts/3/1966. At 72 h post infection, mice received a single treatment of 46B8 or a control IgG intravenously at 5, 15 or 45 mg kg−1. Survival curves are shown. Each group contains eight mice. Log-rank tests of all 46B8 doses versus the control in all infection models give P<0.05.